Company: LICN
Filing Date: 2025-01-29
Form Type: 424B5
Source: 0001213900-25-007741
Chunk: 104

Company: Lichen International Ltd
Filing Date: 2025-01-29
Form: 424B5
Chunk 104
---
 materially and adversely affect
our financial condition and results of operations and could cause the value of our securities to significantly decline or be worthless.
See “Risk Factors — Risks Related to Doing Business in China — The filing, approval or other administration
requirements of the Chinese Securities Regulatory Commission (the “CSRC”) or other PRC government authorities may be required
in connection with our future offshore offering under PRC law, and, if required, we cannot predict whether or for how long we will be
able to complete the filing procedure with the CSRC and obtain such approval or complete such filing, as applicable” on page 14.

As of the date of this prospectus, according to our PRC counsel,Tianyuan Law Firm, although we are required to complete the filing procedure in connection with our offerings under the Trial Measures, no relevant PRC laws or regulations in effect require that we obtain permission from any PRC authorities to issue securities to foreign investors, and we have not received any inquiry, notice, warning, sanction, or any regulatory objection to this offering from the CSRC, the CAC, or any other PRC authorities that have jurisdiction over our operations.

<div align='center'>11</div>

However, there remains some uncertainty as to
how the M&A Rules will be interpreted or implemented in the context of an overseas offering and the opinions summarized above are
subject to any new laws, rules and regulations or detailed implementations and interpretations in any form relating to the M&A Rules.
We cannot assure you that relevant PRC government agencies, including the CSRC, would reach the same conclusion as our PRC counsel does,
and hence we may face regulatory actions or other sanctions from the CSRC or other PRC regulatory agencies. These regulatory agencies
may impose fines and penalties on our operations in China, limit our operating privileges in China, delay or restrict the repatriation
of the proceeds from this offering into China, restrict or prohibit the payments or remittance of dividends by our PRC subsidiaries or
take other actions that could have a material adverse effect on our business, financial condition, results of operations, reputation and
prospects, as well as the trading price of the shares. It is uncertain when and whether the Company will be required to obtain permission
from the PRC government to list on U.S. exchanges in the future, and even when such permission is obtained, whether it will be denied
or rescinded.

The PRC government may intervene or influence
our operations at any time, which